Skip to main content

The New Standard for

Fungal Diagnostics

Find out more

Global Public Health Problem

Invasive fungal infections are silent killers, leading to more deaths annually than malaria, tuberculosis, or breast cancer.

Due to their rising incidence, high morbidity, and mortality rates, the WHO now recognises them as a global healthcare threat, with $8 Billion spent on antifungal drugs each year.

Early diagnosis of fungal infection is critical to effective treatment.

Diagnostic Challenges

Diagnosis of fungal infection is challenging, partly because their symptoms are nonspecific or often overlap with bacterial or viral infections. Traditional culture-based diagnostic assays are characterised by long turnaround times and low specificity and sensitivity. This means fungal infections are often treated with an empiric approach, leading to patients being prescribed inappropriate treatments and increasing harmful resistance to antifungal drugs.

Diagnostic advances

The development of laboratory-based and point-of-care tests can revolutionise the diagnostic workflow. The rapid and accurate identification of fungal infections in a culture-free workflow allows the initiation of species-oriented therapy as soon as possible and the creation of in-house test combinations suitable for different settings and diagnostics needs.

Clinical benefits of a diagnostic-led approach


Real-time therapeutic decision making


Reduced drug resistance through appropriate prescribing


Implementing local testing programme


Compatible with existing laboratory equipment


Better resources utilisation


Improved patient care

Our upcoming events

More events